Peptides · Evidence-graded entry

Argireline (acetyl hexapeptide-8): what the evidence shows

Name: Argireline (acetyl hexapeptide-8): what the evidence shows
Creator: SoftMaxx AI Editorial
Published: 2026-09-30

Argireline, evidence-graded: the best support is randomized human trials. Citations checked against PubMed and regulator records.

Written by SoftMaxx AI editorial · Citations checked against PubMed records · Updated 2026-10-01 · Not medically reviewed · How we grade evidence

SoftMaxx AI sells no peptides and takes no vendor money.

The verdict · strongest evidence Human RCT

Human RCT A handful of small, short human trials exist: a 2002 study in the paper that introduced it (wrinkle depth reduced by up to 30% after 30 days; its emulsion is in the doses table), a 60-person randomized, placebo-controlled trial in Chinese subjects (4 weeks) reporting benefit, a 21-person three-arm randomized trial of an acetylhexapeptide-3 cream in which a palmitoyl pentapeptide-4 cream did better, and a 19-person split-face study where the difference was not significant. The 21-person trial reports acetylhexapeptide-3; CosIng lists acetyl hexapeptide-8; whether these are the same substance is not stated in the abstract.^[1][2][3][4]

What Argireline is

Argireline is a six-amino-acid synthetic peptide, Ac-EEMQRR-NH2 ^[1]; a skin-penetration study names the same sequence acetyl hexapeptide-8 ^[5]. It is patterned on the N-terminal end of SNAP-25 and reported to inhibit vesicle docking by blocking formation of the ternary SNARE complex ^[2]. It was designed as a topical ingredient that mimics the action of botulinum toxins ^[1], and a 2025 review calls it widely used in topical formulations ^[6].

In vitro (cells) In the developers' lab tests it interfered with the formation or stability of the SNARE complex that drives calcium-dependent nerve-signal release, and it inhibited neurotransmitter release with much lower efficacy than botulinum toxin A ^[1]; a later trial paper also describes it as interfering with catecholamine release ^[2]. Whether a topical dose reaches facial nerve–muscle junctions is uncertain, per a 2025 review ^[6]: in human cadaver skin most of it washed off the surface, what penetrated stayed mostly in the stratum corneum, and none was detected in the dermis ^[5].^[1][2][6][5]

Claims vs. evidence

Each popular claim, graded by the strongest study behind it. The words in quotation marks are how the claim is marketed; the text after the grade is what the studies show.

Claim as marketedReduces expression lines / crow's feetHuman RCT Small, short (4–8 weeks) trials with mixed results: positive in a 2013 trial (n=60, 3:1 randomisation), weaker than palmitoyl pentapeptide-4 in a 2023 three-arm trial of an acetylhexapeptide-3 cream (n=21; the abstract does not state whether this is the same substance as acetyl hexapeptide-8), non-significant in a 2023 split-face study (n=19).^[2][3][4][1]
Claim as marketedWorks like Botox / 'Botox in a bottle'In vitro (cells) In lab tests it inhibited neurotransmitter release with much lower efficacy than botulinum toxin A ^[1]. A 2025 review says whether it reaches nerve–muscle junctions is uncertain, and how it might inhibit muscle contraction when applied to skin is incompletely understood ^[6]. In human cadaver skin, none was detected in the dermis ^[5].^[1][6][5]
Claim as marketedEnhanced wrinkle effect via microneedle patchesHuman RCT Randomized, double-blind split-face trial in 52 Korean women (50 finished), one patch a week for 29 days: wrinkles improved in every group, including the plain hyaluronic-acid patch, and the argireline patch improved wrinkles significantly more than the plain patch. The abstract does not say how large that extra improvement was.^[7]
Claim as marketedGeneral anti-aging benefit of topical peptidesExpert review A 2026 meta-analysis of 19 randomized trials of oral and topical peptides found a modest pooled wrinkle effect, largely driven by oral polypeptides.^[8]

Common myths, checked

Common beliefArgireline is 'Botox in a bottle'.Human RCT It is patterned on part of SNAP-25 and, in lab tests, inhibited neurotransmitter release with much lower efficacy than botulinum toxin A. In human cadaver skin most of it washed off; about 0.2% of the applied dose was found in the outer layer, 0.01% in the epidermis and none in the dermis. Its human wrinkle trials are small and mixed: a 60-person trial was positive over 4 weeks, and a 19-person split-face study found no significant difference.^[2][1][5][4]
Common beliefHigher percentage = stronger effect.Expert review The cosmetic safety panel found it safe in the present practices of use at the concentrations listed in the doses table, and the data insufficient to judge higher concentrations. That is a safety ceiling, not evidence that a higher percentage works better.^[9]
Common beliefIt paralyzes facial muscles / causes sagging.In vitro (cells) We found no human report of muscle weakness or sagging from topical argireline. In human cadaver skin none was detected in the dermis, and a 2025 review says whether it reaches nerve–muscle junctions is uncertain. A 19-person study reported no significant adverse events.^[5][6][4]

Doses used in studies (not a recommendation)

These are the amounts given to the people, animals or cells in the cited studies, copied as reported. They are a record of what was tested, not dosing instructions, and nothing here says what you should take.

Studied in	Route	Amount reported	How often	How long	n	Source
Humans	topical (oil-in-water emulsion)	emulsion described as containing 10% of the hexapeptide	not stated in abstract	30 days	—	^[1] healthy women volunteers (pilot; number not stated in abstract)
Humans	topical, applied to periorbital wrinkles (formulation not stated in abstract)	concentration not stated in abstract	twice daily	4 weeks	60	^[2] 60 Chinese adults with periorbital wrinkles
Humans	topical cream to periorbital area	not stated in abstract	twice daily	8 weeks	21	^[3] 21 Indonesian women aged 26–55
Humans	topical cosmetic use (safety ceiling)	safe as used up to 0.005% (peptide) per CIR Expert Panel; data insufficient above that	n/a	n/a	—	^[9] cosmetic consumers

Side effects and risks

Human, small or uncontrolled No significant adverse events, allergic reactions or skin irritation in a 19-person split-face study^[4]
Human RCT No serious adverse effects in a 52-person randomized microneedle-patch trial^[7]

Regulatory status (checked 2026-09-30)

United States (FDA)We found no FDA-approved product containing argireline in Drugs@FDA (searched 2026-10-01). (FDA: Drugs@FDA search: argireline — no approved product found) FDA does not approve cosmetic products or ingredients (other than color additives) before they go on the market, and a product intended to affect the structure or any function of the body is legally a drug. (FDA: Is It a Cosmetic, a Drug, or Both?)
CanadaWe found no product containing argireline in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada: Health Canada Drug Product Database search: argireline — no product found)
Sport (WADA)WADA’s Prohibited List does not name argireline. WADA states that topical cosmetic products may contain prohibited peptides or growth factors and that using cosmetic products containing such substances is prohibited; we found no WADA statement on whether argireline is one of them. (WADA: World Anti-Doping Code International Standard Prohibited List 2026; WADA: World Anti-Doping Agency Prohibited List)

Official sources: FDA: Is It a Cosmetic, a Drug, or Both? · WADA: World Anti-Doping Code International Standard Prohibited List 2026 · WADA: World Anti-Doping Agency Prohibited List

Report a side effect

If something went wrong after using any product, tell a clinician and report it. Reports are how regulators find contaminated or mislabeled products.

FDA MedWatch (United States)
Canada Vigilance Program (Canada)

Common questions

Does Argireline work like Botox?

Human RCT It is patterned on part of SNAP-25 and, in lab tests, inhibited neurotransmitter release with much lower efficacy than botulinum toxin A. In human cadaver skin most of it washed off; about 0.2% of the applied dose was found in the outer layer, 0.01% in the epidermis and none in the dermis. Its human wrinkle trials are small and mixed: a 60-person trial was positive over 4 weeks, and a 19-person split-face study found no significant difference.^[2][1][5][4]

Why is Argireline called Botox in a bottle?

In vitro (cells) Its developers designed it to mimic the action of botulinum toxins. In lab tests it inhibited neurotransmitter release with much lower efficacy than botulinum toxin A ^[1]. A 2025 review says whether it reaches nerve–muscle junctions is uncertain, and how it might inhibit muscle contraction when applied to skin is incompletely understood ^[6]. In human cadaver skin, none was detected in the dermis ^[5].^[1][6][5]

Does Argireline cause sagging?

In vitro (cells) We found no human report of muscle weakness or sagging from topical argireline. In human cadaver skin none was detected in the dermis, and a 2025 review says whether it reaches nerve–muscle junctions is uncertain. A 19-person study reported no significant adverse events.^[5][6][4]

How long does Argireline take to work?

The human studies cited here measured results after 28 days to 8 weeks. That is how long the studies ran, not a promise of results.^{[1][2][3][4][7]}

References

Every reference below was matched to its PubMed or DOI record (title checked) before publication. "Verified" means the paper exists and is the one named; what it supports is stated next to each claim.

A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci (2002). PubMed 18498523 DOI
The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol (2013). PubMed 23417317 DOI
Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol (2023). PubMed 36909866
Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia® Complexion Analysis camera system for objective skin analysis. GMS Interdiscip Plast Reconstr Surg DGPW (2023). PubMed 38024099 DOI
In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol (2015). PubMed 24754410 DOI
Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci (2025). PubMed 40565185 DOI
Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Ann Dermatol (2019). PubMed 33911590 DOI
Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne) (2026). PubMed 41924746 DOI
Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol (2025). PubMed 40673537 DOI

Written by SoftMaxx AI editorial · Citations checked against PubMed records · Updated 2026-10-01 · Not medically reviewed. Editorial standards · Evidence grading and update log.